The biotech's recent momentum is showing no signs of cooling off, despite its jaw-dropping valuation.
News & Analysis: Exact Sciences
Easier ways to look for solid tumors are closer than you think.
These look like great picks to buy in May before you go away.
A new study is planned that could someday reshape colon cancer screenings.
Exact Sciences stock hit an all-time high last month, despite a sour market for biotech stocks.
EXAS earnings call for the period ending March 31, 2019.
The maker of the Cologuard colorectal cancer screening test reported tremendous revenue growth -- but a worsening bottom line.
If you thought Monday was exciting, wait until you see what's on the slate for the rest of the week.
Here's why Cologuard's popularity will continue to climb for a long time.
Worries about Obamacare have taken a toll on shares of the diagnostics test company.